{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:17Z","timestamp":1787026517374,"version":"build-2736575974"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>CD93 is a transmembrane receptor that is mainly expressed on endothelial cells. A recent study found that upregulated CD93 in tumor vessels is essential for tumor angiogenesis in several cancers. However, the underlying mechanisms are largely unexplored. Our present research systematically analyzed the characteristics of CD93 in tumor immunotherapy among 33 cancers. CD93 levels and co-expression of CD93 on cancer and stromal cells were detected using public databases and multiple immunofluorescence staining. The Kaplan-Meier (KM) analysis identified the predictive role of CD93 in these cancer types. The survival differences between CD93 mutants and WT, CNV groups, and methylation were also investigated. The immune landscape of CD93 in the tumor microenvironment was analyzed using the SangerBox, TIMER 2.0, and single-cell sequencing. The immunotherapy value of CD93 was predicted through public databases. CD93 mRNA and protein levels differed significantly between cancer samples and adjacent control tissues in multiply cancer types. CD93 mRNA expression associated with patient prognosis in many cancers. The correlation of CD93 levels with mutational status of other gene in these cancers was also analyzed. CD93 levels significantly positively related to three scores (immune, stromal, and extimate), immune infiltrates, immune checkpoints, and neoantigen expression.. Additionally, single-cell sequencing revealed that CD93 is predominantly co-expressed on tumor and stromal cells, such as endothelial cells, cancer-associated fibroblasts (CAFs), neutrophils, T cells, macrophages, M1 and M2 macrophages. Several immune-related signaling pathways were enriched based on CD93 expression, including immune cells activation and migration, focal adhesion, leukocyte transendothelial migration, oxidative phosphorylation, and complement. Multiple immunofluorescence staining displayed the relationship between CD93 expression and CD8, CD68, and CD163 in these cancers. Finally, the treatment response of CD93 in many immunotherapy cohorts and sensitive small molecules was predicted from the public datasets. CD93 expression is closely associated with clinical prognosis and immune infiltrates in a variety of tumors. Targeting CD93-related signaling pathways in the tumor microenvironment may be a novel therapeutic strategy for tumor immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2022.907182","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:49:25Z","timestamp":1666831765000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Identify the immune characteristics and immunotherapy value of CD93 in the pan-cancer based on the public data sets"],"prefix":"10.3389","volume":"13","author":[{"given":"Aiyuan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaoqu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wantao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistic","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-019-0079-0","article-title":"Accumulation of genetic and epigenetic alterations in normal cells and cancer risk","volume":"3","author":"Takeshima","year":"2019","journal-title":"NPJ Precis Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3892\/ijo.2022.5302","article-title":"Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review)","volume":"60","author":"Lu","year":"2022","journal-title":"Int J Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-008-9661-9","article-title":"Cancer is a preventable disease that requires major lifestyle changes","volume":"25","author":"Anand","year":"2008","journal-title":"Pharm Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2852","article-title":"Advances in chemical carcinogenesis: a historical review and prospective","volume":"68","author":"Loeb","year":"2008","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2019.961","article-title":"Innovative approaches for cancer treatment: current perspectives and new challenges","volume":"13","author":"Pucci","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"B7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.271","article-title":"The tumor microenvironment and its role in promoting tumor growth","volume":"27","author":"Whiteside","year":"2008","journal-title":"Oncogene"},{"key":"B11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41416-018-0327-z","article-title":"The clinical role of the TME in solid cancer","volume":"120","author":"Giraldo","year":"2019","journal-title":"Br J Cancer"},{"key":"B12","article-title":"Cancer immunotherapy: a promising dawn in cancer research","volume":"10","author":"Bondhopadhyay","year":"2020","journal-title":"Am J Blood Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"151875","DOI":"10.1016\/j.imbio.2019.11.010","article-title":"Promising approaches in cancer immunotherapy","volume":"225","author":"Taefehshokr","year":"2020","journal-title":"Immunobiology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00933","article-title":"ATM Mutations benefit bladder cancer patients treated with immune checkpoint inhibitors by acting on the tumor immune microenvironment","volume":"11","author":"Yi","year":"2020","journal-title":"Front Genet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02668-8","article-title":"ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer","volume":"70","author":"Zhang","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.628966","article-title":"PDIA5 is correlated with immune infiltration and predicts poor prognosis in gliomas","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97459","article-title":"CD93 promotes beta1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis","volume":"128","author":"Lugano","year":"2018","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12974-020-01797-2","article-title":"Glioblastoma hijacks microglial gene expression to support tumor growth","volume":"17","author":"Maas","year":"2020","journal-title":"J Neuroinflamm"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108663","article-title":"Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells","volume":"34","author":"Riether","year":"2021","journal-title":"Cell Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/febs.14985","article-title":"C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation","volume":"286","author":"Khan","year":"2019","journal-title":"FEBS J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3636","article-title":"Elevated expression of the c-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival","volume":"75","author":"Langenkamp","year":"2015","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-021-03543-3","article-title":"CD93 a potential player in cytotrophoblast and endothelial cell migration","volume":"387","author":"Fantone","year":"2022","journal-title":"Cell Tissue Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000259593.07661.1e","article-title":"Endothelial cell migration during angiogenesis","volume":"100","author":"Lamalice","year":"2007","journal-title":"Circ Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10456-019-09689-7","article-title":"Role of melatonin in controlling angiogenesis under physiological and pathological conditions","volume":"23","author":"Ma","year":"2020","journal-title":"Angiogenesis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1348-0421.2006.tb03774.x","article-title":"Regulation of CD93 cell surface expression by protein kinase c isoenzymes","volume":"50","author":"Ikewaki","year":"2006","journal-title":"Microbiol Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.793445","article-title":"Pan-cancer analysis identified CD93 as a valuable biomarker for predicting patient prognosis and immunotherapy response","volume":"8","author":"Tong","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.817965","article-title":"CD93 correlates with immune infiltration and impacts patient immunotherapy efficacy: A pan-cancer analysis","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2764","article-title":"The cancer genome atlas pan-cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat Genet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2653","article-title":"The genotype-tissue expression (GTEx) project","volume":"45","author":"Consortium","year":"2013","journal-title":"Nat Genet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33283","article-title":"muTarget: A platform linking gene expression changes and mutation status in solid tumors","volume":"148","author":"Nagy","year":"2021","journal-title":"Int J Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: Gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"B33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1070","article-title":"KEGG as a reference resource for gene and protein annotation","volume":"44","author":"Kanehisa","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-10-277","article-title":"CellMiner: a relational database and query tool for the NCI-60 cancer cell lines","volume":"10","author":"Shankavaram","year":"2009","journal-title":"BMC Genomics"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32369","article-title":"ROCplot.org: Validating predictive biomarkers of chemotherapy\/hormonal therapy\/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients","volume":"145","author":"Fekete","year":"2019","journal-title":"Int J Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgab024","article-title":"Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies","volume":"42","author":"Menyhart","year":"2021","journal-title":"Carcinogenesis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01378-4","article-title":"Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer","volume":"23","author":"Sanchez","year":"2021","journal-title":"Breast Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"13380","DOI":"10.1038\/s41598-017-13942-8","article-title":"Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues","volume":"7","author":"Parra","year":"2017","journal-title":"Sci Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","article-title":"Neoantigen vaccine: an emerging tumor immunotherapy","volume":"18","author":"Peng","year":"2019","journal-title":"Mol Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.672356","article-title":"Neoantigen: A new breakthrough in tumor immunotherapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3892\/or.2020.7856","article-title":"Targeting eIF4A using rocaglate CR131B sensitizes gallbladder cancer cells to TRAILmediated apoptosis through the translational downregulation of cFLIP","volume":"45","author":"Cao","year":"2021","journal-title":"Oncol Rep"},{"key":"B44","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1038\/s41467-019-13086-5","article-title":"eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma","volume":"10","author":"Chan","year":"2019","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2010.01.042","article-title":"Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing","volume":"18","author":"Brasca","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv131","article-title":"Development of cell-cycle checkpoint therapy for solid tumors","volume":"45","author":"Tamura","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1021\/jm8001839","article-title":"Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro","volume":"51","author":"Gediya","year":"2008","journal-title":"J Med Chem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun Signal"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26051","article-title":"Combination of nanotechnology with vascular targeting agents for effective cancer therapy","volume":"233","author":"Jahanban-Esfahlan","year":"2018","journal-title":"J Cell Physiol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12943-019-0971-9","article-title":"Exploiting vulnerabilities of cancer by targeting nuclear receptors of stromal cells in tumor microenvironment","volume":"18","author":"Cheng","year":"2019","journal-title":"Mol Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13287-016-0363-7","article-title":"Mechanisms of mesenchymal stem\/stromal cell function","volume":"7","author":"Spees","year":"2016","journal-title":"Stem Cell Res Ther"},{"key":"B54","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12943-019-0960-z","article-title":"Recent advances in understanding tumor stroma-mediated chemoresistance in breast cancer","volume":"18","author":"Plava","year":"2019","journal-title":"Mol Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00491","article-title":"Macrophage cytokines: Involvement in immunity and infectious diseases","volume":"5","author":"Arango Duque","year":"2014","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2741\/3613","article-title":"Cancer associated fibroblasts (CAFs) in tumor microenvironment","volume":"15","author":"Xing","year":"2010","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.04.042","article-title":"A CXCL1 paracrine network links cancer chemoresistance and metastasis","volume":"150","author":"Acharyya","year":"2012","journal-title":"Cell"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00188","article-title":"Tumor-associated macrophages: Recent insights and therapies","volume":"10","author":"Zhou","year":"2020","journal-title":"Front Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00017","article-title":"And exhaustion in cancer","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-0721-z","article-title":"Large-Scale public data reuse to model immunotherapy response and resistance","volume":"12","author":"Fu","year":"2020","journal-title":"Genome Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1039\/b917766c","article-title":"A collaborative database and computational models for tuberculosis drug discovery","volume":"6","author":"Ekins","year":"2010","journal-title":"Mol Biosyst"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2019.06.021","article-title":"Drug databases and their contributions to drug repurposing","volume":"112","author":"Masoudi-Sobhanzadeh","year":"2020","journal-title":"Genomics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.907182\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:49:30Z","timestamp":1666831770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.907182\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":64,"alternative-id":["10.3389\/fimmu.2022.907182"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.907182","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"article-number":"907182"}}